Breaking News Instant updates and real-time market news.

SNDX

Syndax

$5.26

(0.00%)

10:36
04/01/19
04/01
10:36
04/01/19
10:36

Syndax updates findings from melanoma, NSCLC cohorts of ENCORE 601 trial

Syndax Pharmaceuticals (SNDX) announced the presentation of updated findings from the melanoma and non-small cell lung cancer, or NSCLC, cohorts of ENCORE 601, the company's Phase 1b/2 trial evaluating the efficacy and safety of entinostat, its once-weekly, oral, small molecule, class I HDAC inhibitor, in combination with Keytruda, Merck's (MRK) anti-PD-1 therapy. The data were presented during oral presentations at the American Association of Cancer Research Annual Meeting. The company presented results from the ENCORE 601 melanoma cohort that enrolled patients whose disease had progressed on or after anti-PD-1 therapy. Of 53 patients treated, a confirmed objective response was observed in 19% of patients per irRECIST criteria, with a clinical benefit rate of 36%. Median duration of response is 13 months. Four responders, all of whom have been on study therapy for over a year, currently remain on treatment. Efficacy results in patients who also received prior Yervoy therapy were consistent with the overall population. The entinostat-pembrolizumab combination was well tolerated with a manageable toxicity profile. Briggs Morrison, M.D., CEO of Syndax, said, "Both indications represent areas of high unmet need and we believe that available data warrant consideration to move the entinostat-pembrolizumab combination into one or more registration trials. As previously communicated, we look forward to determining next steps for the combination program following availability of overall survival results from E2112, our Phase 3 registration trial of entinostat plus exemestane in HR+, HER2- breast cancer, the next interim readout of which is expected in the second quarter of this year."

  • 07

    May

SNDX Syndax
$5.26

(0.00%)

01/07/19
RILY
01/07/19
INITIATION
Target $40
RILY
Buy
Syndax resumed with a Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty resumed coverage on Syndax with a Buy and $40 price target.
03/08/19
HCWC
03/08/19
NO CHANGE
Target $16
HCWC
Buy
Syndax price target lowered to $16 from $22 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for Syndax Pharmaceuticals to $16 due to removing entinostat in combination with checkpoint inhibitors in non-small cell lung cancer and melanoma from his valuation. The analyst keeps a Buy rating on the shares.
03/08/19
NOMU
03/08/19
NO CHANGE
Target $16
NOMU
Buy
Syndax price target raised to $16 from $12 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Syndax Pharmaceuticals to $16 following the company's Q4 results and keeps a Buy rating on the shares. The analyst says Syndax is "prioritizing for success" in 2019 and beyond.
03/08/19
BTIG
03/08/19
NO CHANGE
Target $19
BTIG
Buy
Syndax price target lowered to $19 from $29 at BTIG
BTIG analyst Robert Hazlett lowered his price target on Syndax to $19 after its announced miss in the primary Progression-free survival Phase 2 study for Entinostat immuno-oncology combinations in Triple-negative breast cancer and ovarian cancer. The analyst says the company is now prioritizing its pipeline to focus on Entinostat in breast cancer with upcoming readouts expected in Q2. Hazlett is keeping his Buy rating on Syndax.

TODAY'S FREE FLY STORIES

02:55
11/12/19
11/12
02:55
11/12/19
02:55
General news
FX Update: The yen took a rotation lower »

FX Update: The yen took a…

01:50
11/12/19
11/12
01:50
11/12/19
01:50
General news
Asian Market Update »

Asian Market Update:…

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:44
11/11/19
11/11
20:44
11/11/19
20:44
Earnings
Nesco Holdings cuts FY19 revenue view to $255M-$262M from $278M »

One estimate $279.6M. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSCO

Nesco Holdings

$4.75

0.04 (0.85%)

20:42
11/11/19
11/11
20:42
11/11/19
20:42
Earnings
Nesco Holdings reports Q3 EPS (45c), one estimate 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FTK

Flotek

$1.86

-0.1 (-5.10%)

20:29
11/11/19
11/11
20:29
11/11/19
20:29
Earnings
Flotek reports Q3 EPS (19c), one estimate (23c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RF

Regions Financial

$16.77

-0.1 (-0.59%)

20:27
11/11/19
11/11
20:27
11/11/19
20:27
Downgrade
Regions Financial rating change at BMO Capital »

Regions Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

TSN

Tyson Foods

$82.70

0.12 (0.15%)

, ROK

Rockwell Automation

$180.00

2.25 (1.27%)

20:25
11/11/19
11/11
20:25
11/11/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TSN

Tyson Foods

$82.70

0.12 (0.15%)

ROK

Rockwell Automation

$180.00

2.25 (1.27%)

DHI

D.R. Horton

$52.65

1.535 (3.00%)

CBS

CBS

$39.21

1.09 (2.86%)

AAP

Advance Auto Parts

$168.41

1.17 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

RMTI

Rockwell Medical

$1.92

0.07 (3.78%)

20:01
11/11/19
11/11
20:01
11/11/19
20:01
Recommendations
Rockwell Medical analyst commentary at Piper Jaffray »

Rockwell Medical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

APYX

Apyx Medical

$7.22

0.24 (3.44%)

19:39
11/11/19
11/11
19:39
11/11/19
19:39
Recommendations
Apyx Medical analyst commentary at Piper Jaffray »

Apyx Medical price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

FOE

Ferro

$12.58

0.07 (0.56%)

, APYX

Apyx Medical

$7.22

0.24 (3.44%)

18:59
11/11/19
11/11
18:59
11/11/19
18:59
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ferro…

FOE

Ferro

$12.58

0.07 (0.56%)

APYX

Apyx Medical

$7.22

0.24 (3.44%)

KEM

Kemet

$23.03

-0.51 (-2.17%)

ICUI

ICU Medical

$168.41

1.43 (0.86%)

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

GO

Grocery Outlet

$31.09

-0.06 (-0.19%)

CMLS

Cumulus Media

$13.59

0.07 (0.52%)

FGEN

FibroGen

$35.37

-6.24 (-15.00%)

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

LYV

Live Nation

$64.47

1.31 (2.07%)

FLNT

Fluent

$2.54

0.11 (4.53%)

ASUR

Asure Software

$9.20

0.01 (0.11%)

UGI

UGI Corporation

$46.21

-0.35 (-0.75%)

HBM

Hudbay Minerals

$3.66

-0.09 (-2.40%)

FPI

Farmland Partners

$6.66

-0.125 (-1.84%)

RETA

Reata Pharmaceuticals

$213.52

1.48 (0.70%)

JCOM

j2 Global

$100.62

0.23 (0.23%)

PCG

PG&E

$6.24

-0.23 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 19

    Nov

  • 09

    Dec

  • 07

    Jan

CRL

Charles River

$131.58

1.19 (0.91%)

18:57
11/11/19
11/11
18:57
11/11/19
18:57
Hot Stocks
Charles River CEO: We are pleased with the demand curve »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.24

-0.23 (-3.55%)

18:44
11/11/19
11/11
18:44
11/11/19
18:44
Periodicals
PG&E offers $13.5B in compensation to victims of CA fires, Bloomberg says »

PG&E is offering to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 07

    Jan

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:27
11/11/19
11/11
18:27
11/11/19
18:27
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Kemet up 14.7% to $26.40…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NCLH

Norwegian Cruise Line

$51.90

0.07 (0.14%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Hot Stocks
Norwegian Cruise Line CEO: North American consumer is alive and well »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOE

Ferro

$12.58

0.07 (0.56%)

18:23
11/11/19
11/11
18:23
11/11/19
18:23
Earnings
Ferro reports Q3 adjusted EPS 35c, consensus 28c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:09
11/11/19
11/11
18:09
11/11/19
18:09
Hot Stocks
Yageo to acquire Kemet for $27.20 per share in cash, or $1.8B »

Yageo and Kemet announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PAR

Par Technology

$30.23

1.07 (3.67%)

18:08
11/11/19
11/11
18:08
11/11/19
18:08
Recommendations
Par Technology analyst commentary at Jefferies »

Par Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$23.03

-0.51 (-2.17%)

18:06
11/11/19
11/11
18:06
11/11/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Kemet »

Yageo to acquire Kemet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

CSX

CSX

$73.93

-0.08 (-0.11%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Downgrade
CSX rating change at Deutsche Bank »

CSX downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

TDW

Tidewater

$17.14

-0.34 (-1.95%)

18:03
11/11/19
11/11
18:03
11/11/19
18:03
Earnings
Tidewater reports Q3 adjusted EPS (99c), may not compare to consensus (10c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

UNVR

Univar

$23.87

-0.08 (-0.33%)

17:57
11/11/19
11/11
17:57
11/11/19
17:57
Hot Stocks
Univar named EMEA distributor for Kaopolite Abrasive in Europe »

Univar B.V., a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$46.48

0.44 (0.96%)

17:56
11/11/19
11/11
17:56
11/11/19
17:56
Hot Stocks
NexPoint Residential acquires three-property portfolio in Las Vegas for $241M »

NexPoint Residential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Breaking Hot Stocks news story on DXC Technology »

DXC reverses course, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

FLNT

Fluent

$2.54

0.11 (4.53%)

17:40
11/11/19
11/11
17:40
11/11/19
17:40
Hot Stocks
Fluent drops over 22% after reporting Q3 results, lowers FY19 revenue view »

Shares of Fluent are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

17:38
11/11/19
11/11
17:38
11/11/19
17:38
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.